Repotrectinib
Sign in to save this workspacePrimary targets: ROS_ROS1 · FDA status: FDA Approved
Selectivity scorecard
KISS
84.21
Gini
0.608
CATDS
0.008
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Repotrectinib. Strongest target: ROS_ROS1 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ROS_ROS1 | 100.0% | 0.0% |
| 2 | TRKB | 99.8% | 0.2% |
| 3 | TXK | 99.8% | 0.2% |
| 4 | EPHA2 | 99.6% | 0.4% |
| 5 | ALK | 99.4% | 0.6% |
| 6 | BMX_ETK | 99.3% | 0.7% |
| 7 | DDR1 | 99.3% | 0.7% |
| 8 | FAK_PTK2 | 99.2% | 0.8% |
| 9 | ACK1 | 99.0% | 1.0% |
| 10 | TRKA | 98.9% | 1.1% |
| 11 | TRKC | 98.9% | 1.1% |
| 12 | FGR | 98.9% | 1.1% |
| 13 | LYN | 98.7% | 1.3% |
| 14 | MUSK | 98.6% | 1.4% |
| 15 | LCK | 98.6% | 1.4% |
| 16 | YES_YES1 | 98.4% | 1.6% |
| 17 | BLK | 98.4% | 1.6% |
| 18 | JAK2 | 98.3% | 1.7% |
| 19 | DDR2 | 98.3% | 1.8% |
| 20 | EPHB4 | 98.2% | 1.8% |
Selectivity landscape
Where Repotrectinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Repotrectinib.
Atlas insights for Repotrectinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 3626.57 | |
| ALLOGRAFT_REJECTION | 12956.21 | |
| ANDROGEN_RESPONSE | 2075.73 | |
| ANGIOGENESIS | 2134.74 | |
| APICAL_JUNCTION | 12335.68 | |
| APICAL_SURFACE | 1313.64 | |
| APOPTOSIS | 9337.04 | |
| BILE_ACID_METABOLISM | 1311.23 | |
| CHOLESTEROL_HOMEOSTASIS | 1607.44 | |
| COAGULATION | 1584.94 | |
| COMPLEMENT | 7491.81 | |
| DNA_REPAIR | 2023.81 | |
| E2F_TARGETS | 5678.90 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 2897.40 | |
| ESTROGEN_RESPONSE_EARLY | 5213.04 | |
| ESTROGEN_RESPONSE_LATE | 4516.06 | |
| FATTY_ACID_METABOLISM | 941.37 | |
| G2M_CHECKPOINT | 5826.44 | |
| GLYCOLYSIS | 3968.07 | |
| HEDGEHOG_SIGNALING | 1254.23 | |
| HEME_METABOLISM | 2719.76 | |
| HYPOXIA | 5193.94 | |
| IL2_STAT5_SIGNALING | 4490.33 | |
| IL6_JAK_STAT3_SIGNALING | 7921.83 | |
| INFLAMMATORY_RESPONSE | 7020.04 | |
| INTERFERON_ALPHA_RESPONSE | 1192.07 | |
| INTERFERON_GAMMA_RESPONSE | 8612.79 | |
| KRAS_SIGNALING_DN | 1577.31 | |
| KRAS_SIGNALING_UP | 4339.81 | |
| MITOTIC_SPINDLE | 8174.52 | |
| MTORC1_SIGNALING | 4809.31 | |
| MYC_TARGETS_V1 | 3636.93 | |
| MYC_TARGETS_V2 | 982.60 | |
| MYOGENESIS | 4680.26 | |
| NOTCH_SIGNALING | 143.46 | |
| OXIDATIVE_PHOSPHORYLATION | 1484.66 | |
| P53_PATHWAY | 4480.50 | |
| PANCREAS_BETA_CELLS | 322.15 | |
| PEROXISOME | 1598.59 | |
| PI3K_AKT_MTOR_SIGNALING | 12071.37 | |
| PROTEIN_SECRETION | 2778.59 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 564.41 | |
| SPERMATOGENESIS | 1918.76 | |
| TGF_BETA_SIGNALING | 2395.82 | |
| TNFA_SIGNALING_VIA_NFKB | 5541.63 | |
| UNFOLDED_PROTEIN_RESPONSE | 1895.53 | |
| UV_RESPONSE_DN | 6601.26 | |
| UV_RESPONSE_UP | 5296.58 | |
| WNT_BETA_CATENIN_SIGNALING | 2579.75 | |
| XENOBIOTIC_METABOLISM | 2659.38 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.832 |
| SRR23303752 | — | 0.831 |
| SRR10899984 | — | 0.820 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.817 |
| aMVAC.P_005_TURBT_S223 | — | 0.814 |
Annotations
Sign in to read and post annotations.
Loading…